|
ELMOD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.25215418431435E-14 |
| Normal-vs-Stage2 |
1.72830000311208E-08 |
| Normal-vs-Stage3 |
1.15463194561016E-14 |
| Normal-vs-Stage4 |
1.62891922173003E-12 |
| Stage1-vs-Stage2 |
6.411800E-01 |
| Stage1-vs-Stage3 |
1.090440E-01 |
| Stage1-vs-Stage4 |
8.264200E-03 |
| Stage2-vs-Stage3 |
1.224650E-01 |
| Stage2-vs-Stage4 |
8.860500E-03 |
| Stage3-vs-Stage4 |
1.817640E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.6553000004027E-07 |
| Normal-vs-Asian |
2.18391971174015E-12 |
| Caucasian-vs-AfricanAmerican |
9.663200E-01 |
| Caucasian-vs-Asian |
4.290000E-01 |
| AfricanAmerican-vs-Asian |
6.705000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.86517468137026E-14 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
3.863200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.8016699243617E-12 |
| Normal-vs-Age(41-60Yrs) |
4.01900734914307E-14 |
| Normal-vs-Age(61-80Yrs) |
1.62680979798324E-12 |
| Normal-vs-Age(81-100Yrs) |
6.894000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.314400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.527610E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.989400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.814200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.644200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.798200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.179840E-03 |
| Classical-VS-Follicular |
3.227200E-01 |
| Classical-VS-Other |
1.114180E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
1.215210E-03 |
| Tall-VS-Other |
5.441000E-01 |
| Tall-VS-Normal |
1.66533453693773E-15 |
| Follicular-VS-Other |
1.335680E-02 |
| Follicular-VS-Normal |
4.78339999832045E-08 |
| Other-VS-Normal |
2.77169999995941E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95399252334028E-14 |
| Normal-vs-N1 |
7.72493180534184E-13 |
| N0-vs-N1 |
1.076420E-01 |
|
|
